Comparison of Pentoxiphylline alone against Pentoxiphylline and N acetyl cysteine in Severe alcoholic hepatitis

A RANDOMIZED CONTROLLED TRIAL OF PENTOXIPHYLLINE VERSUS PENTOXIPHYLLINE AND N-ACETYLCYSTEINE IN SEVERE ALCOHOLIC HEPATITIS

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012577

Enrollment

240

Registered

2018-03-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with severe alcoholic hepatitis

Interventions

Intervention1: Pentoxiphylline alone: Tab Pentoxiphylline 400 mg thrice daily for one month Control Intervention1: Pentoxiphylline and N acetylcysteine: Tab Pentoxiphylline 400 mg thrice daily and Tab

Eligibility

Inclusion criteria

Inclusion criteria: Patients with severe alcoholic hepatitis ie patients with Maddrey DF more than 32

Exclusion criteria

Exclusion criteria: Hepatic encephalopathy hepatorenal syndrome GI bleed sepsis multiorgan dysfunction Viral hepatitis autoimmune hepatitis drug induced hepatitis

Design outcomes

Primary

Measure	Time frame
Survival of patients between two groupsTimepoint: At ninety days	—

Secondary

Measure	Time frame
LFT PT INRTimepoint: At thirty and ninety days	—

Countries

India

Contacts

Public ContactDr Deepak Suvarna

JSS HOSPITAL

dr.deepaksuvarna@gmail.com9964380249

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026